The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Activated Partial Thromboplastin Time

Activated Partial Thromboplastin Time

Activated Partial Thromboplastin Time (aPTT) is a laboratory test that measures the time it takes for blood to clot.
It is used to assess the function of the intrinsic and common pathways of the coagulation cascade.
The aPTT test is commonly used to monitor patients receiving anticoagulant therapy, such as heparin, and to diagnose certain bleeding disorders.
Optimizing aPTT research can be achived through the use of AI-driven comparisons to locate the best protocols from literature, pre-prints, and patents, enhancing reproducibilty and accuaracy to take aPTT research to the next level.

Most cited protocols related to «Activated Partial Thromboplastin Time»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Activated Partial Thromboplastin Time Axilla Bacteremia Blood Blood Coagulation Disorders Bronchoalveolar Lavage Fluid Chinese Congenital Abnormality COVID 19 Echocardiography Electrocardiography Fever Heart Heart Injuries Hospital Administration Hypersensitivity Hypoproteinemia Kidney Injury, Acute pathogenesis Patients Pneumonia Pneumonia, Ventilator-Associated Respiratory Distress Syndrome, Acute Respiratory System Seafood Secondary Infections Septicemia Septic Shock Serum Albumin Sputum Times, Prothrombin Troponin I
This investigation was performed in the CPCCRN of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (8 (link)). Detailed methods for the TOPICC data collection have been previously described (6 (link)). There were seven sites, and one was composed of two institutions. In brief, patients from newborn to less than 18 years were randomly selected and stratified by hospital from December 4, 2011, to April 7, 2013. Patients from both general/medical and cardiac/cardiovascular PICUs were included. Moribund patients (vital signs incompatible with life for the first 2 hr after PICU admission) were excluded. Only the first PICU admission during hospitalization was included. The protocol was approved by all participating institutional review boards. Other analyses using this database have been published (6 (link), 7 (link), 9 (link), 10 (link)).
Data included descriptive and demographic information (Table 1). Interventions included both surgery and interventional catheterization. Cardiac arrest included closed chest massage within 24 hours before hospitalization or after hospital admission but before PICU admission. Admission source was classified as emergency department, inpatient unit, postintervention unit, or admission from another institution. Diagnosis was classified by the system of primary dysfunction based on the reason for PICU admission; cardiovascular conditions were classified as congenital or acquired.
The primary outcome in this analysis was hospital survival versus death.
Physiologic status was measured using the PRISM physiologic variables (5 (link)) with a shortened time interval (2 hr before PICU admission to 4 hr after admission for laboratory data and the first 4 hr of PICU care for other physiologic variables). For model building, the PRISM components were separated into cardiovascular (heart rate, systolic blood pressure, and temperature), neurologic (pupillary reactivity and mental status), respiratory (arterial Po2, pH, Pco2, and total bicarbonate), chemical (glucose, potassium, blood urea nitrogen, and creatinine), and hematologic (WBC count, platelet count, prothrombin, and partial thromboplastin time) components, and the total PRISM was also separated into neurologic and non-neurologic categories.
The time interval for assessing PRISM data was modified for cardiac patients under 91 days old because some institutions admit infants to the PICU before a cardiac intervention to “optimize” the clinical status but not for intensive care; in these cases, the postintervention period more accurately reflects intensive care. However, in other infants for whom the cardiac intervention is delayed after PICU admission or the intervention is a therapy required because of failed medical management of the acute condition, the routine PRISM data collection time interval is an appropriate reflection of critical illness. Therefore, we identified infants for whom it would be more appropriate to use data from the 4 hours after the cardiac intervention (postintervention time interval) and those for whom using the admission time interval was more appropriate. We operationalized this decision on the conditions likely to present within the first 90 days, the time period when the vast majority of these conditions present (Table 2).
Statistical analyses used SAS 9.4 (SAS Institute Inc., Cary, NC) for descriptive statistics, model development, and fit assessment and R 3.1.1 (The R Foundation for Statistical Computing, Vienna, Austria; http://www.wu.ac.at/statmath) for evaluation of predictive ability. Patient characteristics were descriptively compared and evaluated across sites using the Kruskal-Wallis test for continuous variables and the Pearson chi-square test for categorical variables. The statistical analysis was under the direction of R.H.
The dataset was randomly divided into a derivation set (75%) for model building and a validation set (25%) stratified by the study site. Univariate mortality odds ratios were computed, and variables with a significance level of less than 0.1 were considered candidate predictors for the final model. As was the case for the previously published trichotomous (death, survival with significant new morbidity, and intact survival) model construction, a nonautomated (examined by biostatistician and clinician at each step) backward stepwise selection approach was used to select factors. Multicategorical factors (e.g., diagnostic categories) had factors combined when appropriate per statistical and clinical criteria. Clinician input was included (and paramount) in this process to ensure that the model fit was relevant and consistent with clinical information. Construction of a clinically relevant, sufficiently predictive model using predictors readily available to the clinician took precedence over inclusion based solely on statistical significance. We were cognizant of the existing trichotomous outcome model and attempted, when statistically justified, to create a compatible two-outcome model that could aid in a smooth transition to using the three-outcome approach.
Final candidate models were evaluated based on 2D receiver operating characteristic (ROC) curves (discrimination) and the Hosmer-Lemeshow goodness of fit (calibration). For the entire dataset, goodness of fit with respect to key subgroups was assessed by examining SMRs for descriptive and diagnostic categories not used in the final model. Only categories with at least 10 outcomes in observed and expected cells were used.
Publication 2016
Activated Partial Thromboplastin Time Arteries Bicarbonates Cardiac Arrest Cardiovascular Diseases Cardiovascular System Catheterization Cells Chest Creatinine Critical Illness Diagnosis Discrimination, Psychology Disease Management Ethics Committees, Research Glucose Heart Hospitalization Infant Infant, Newborn Inpatient Intensive Care Massage Operative Surgical Procedures Patients physiology Platelet Counts, Blood Potassium prisma Prothrombin Rate, Heart Reflex Respiratory Diaphragm Respiratory Rate Signs, Vital Systems, Nervous Systolic Pressure Therapeutics Urea Nitrogen, Blood
All injuries are coded according to the Abbreviated Injury Scale (AIS), version 2008. The AIS codebook contains about 2000 different injuries, each one with an individual severity level ranging from 1 (minor) to 6 (actual untreatable). The TR-DGU uses a reduced version with only 450 codes for documentation where similar codes with the same severity level were merged.
The ISS is calculated from the three worst affected body regions as the sum of squares of the respective AIS severity levels [2 (link)]. The New ISS, or NISS, is calculated in a similar way but here the three worst injuries are selected regardless of their location [7 (link)]. The TRISS is a combination of anatomical injury severity (ISS), the physiological response (Revised Trauma Score with consciousness, blood pressure, and respiratory rate), and age. The TRISS has different formulas for blunt and penetrating trauma mechanism. This score has repeatedly been used and adapted to local trauma registries but we used the original coefficients of Champion et al. in this analysis for reasons of comparability [3 (link)].
The RISC score has been developed with about 1,200 cases from the TR-DGU documented in the years 1993 to 2000. Besides the NISS the following categorical variables were used in the RISC: age, head injury, Glasgow Coma Scale (GCS), coagulation (partial thromboplastin time), base deficit, CPR, number of indirect signs of bleeding (low haemoglobin; hypotension, massive transfusion). For most variables, an algorithm for replacing missing values had been established (for details, see [4 (link)]).
Full text: Click here
Publication 2014
Activated Partial Thromboplastin Time Blood Pressure Blood Transfusion Body Regions Coagulation, Blood Consciousness Craniocerebral Trauma Diet, Formula Hemoglobin Injuries physiology Respiratory Rate RNA-Induced Silencing Complex SLC5A5 protein, human Wounds, Penetrating Wounds and Injuries
At study entry, the following parameters were recorded: time from ICU admission, age and sex, and ICD-10 diagnoses of common clinical conditions at admission. At the day of each ACTH test, the following were collected: serum total and free cortisol levels before and 30 and 60 minutes after 250 μg of i.v. ACTH, serum levels of ACTH cortisol-binding globulin (CBG), and albumin. Other laboratory measurements included total white blood cell count, platelet count, activated partial thromboplastin time (aPTT), and prothrombin time (PT). Interventions including type and doses of vasopressor/inotropes, intubation, need for mechanical ventilation, and renal replacement therapy were recorded. Sepsis was defined as the presence of systemic inflammatory response syndrome (SIRS) with a positive microbiologic local (urine, trachea, or other) and/or blood culture. SIRS was defined as two or more of the following criteria: a temperature of >38°C or <35.5°C, a leukocyte count >12 of <4 × 109/L, a heart rate >90 per minute, and a respiratory rate >20 per minute, or the presence of mechanical ventilation. Suspected or microbiologically proven sources of sepsis were recorded. Disease severity was assessed by the acute physiology and chronic health evaluation score (APACHE II) and sequential organ-failure assessment score (SOFA) on the days of the ACTH test, and length of ICU stay and mortality in the ICU and hospital were recorded.
Full text: Click here
Publication 2015
Activated Partial Thromboplastin Time Albumins Blood Culture cortisol binding globulin Diagnosis Hydrocortisone Inotropism Intubation Leukocyte Count Mechanical Ventilation physiology Platelet Counts, Blood Rate, Heart Renal Replacement Therapy Respiratory Rate Septicemia Serum Systemic Inflammatory Response Syndrome Times, Prothrombin Trachea Training Programs Urine Vasoconstrictor Agents
In 1987-89, the ARIC Study recruited to a baseline examination a cohort of 15,792 men and women aged 45-64 years, predominantly whites or African Americans, from four U.S. communities (12 (link)). Participants were re-examined in 1990-92 (93% response), 1993-95 (86%) and 1996-98 (80%). Participants in the ARIC Visit 4 examination serve as the cohort for the present analysis.
CRP was measured in 2008 on plasma frozen at −70°C from Visit 4 by the immunoturbidimetric assay using the Siemens (Dade Behring) BNII analyzer (Dade Behring, Deerfield, Ill), performed according to the manufacturer's protocol. Approximately 4% of samples were split and measured as blinded replicates on different dates to assess repeatability. The reliability coefficient for blinded quality control replicates of CRP was 0.99 (421 blinded replicates). Body mass index was assessed as weight (kg) in a scrub suit divided by height (m) squared. Statins were assessed by reviewing participants' medication containers. After Visit 4, cholesterol-lowering medications were self-reported during annual telephone contact. Factor VIIIc and aPTT were not measured at Visit 4 so the Visit 1 value (3 (link), 13 (link)) was used. Factor V Leiden and the prothrombin G20210A polymorphism were not measured in the whole ARIC cohort.
Participants were followed from Visit 4 (1996-98, n = 11,573) through 2005 to identify hospitalized VTE events. These were validated by physician review using a standardized protocol (14 (link)). A total of 263 VTE events were identified, of which only 7 had been included in our previous analysis of baseline CRP and VTE through June 1997 (3 (link)). Excluding these 7 events had no impact on this analysis, so we chose to include them.
Our hypothesis was that CRP would be associated positively with VTE incidence. From the 11,573 participants at Visit 4, we excluded 320 who were missing CRP; 331 with CRP values >20 mg/L, due to possible acute phase response; 342 who had a prior history of VTE; or 204 who were taking warfarin. This left 10,505 at risk: 8,219 whites, 2,255 African Americans, and 31 others, who were grouped with African Americans for this analysis. Follow-up time ended when the participant had a VTE, died, was lost to follow-up, or else until December 31, 2005. Cox proportional hazards regression was used to model the association between CRP and VTE incidence, and to derive hazard ratios and 95% confidence intervals. Hazard ratios were calculated for each of the four highest quintile groups compared with the first, but also for high CRP categories (90th or 95th percentile) versus all others, to study the possible impact of high CRP on VTE. Covariates included previous VTE risk factors measured in the whole ARIC cohort, measured at Visit 4 unless otherwise specified: age (continuous), race (African American, white), sex/hormone replacement therapy (men, women taking HRT, women not taking HRT), diabetes (yes, no), body mass index (continuous), Visit 1 factor VIIIc, and Visit 1 aPTT. Other factors related to CRP (e.g., smoking, lipid levels, physical activity) were not VTE risk factors in ARIC, and thus not included.
Publication 2009
3,3'-diallyldiethylstilbestrol Activated Partial Thromboplastin Time Acute-Phase Reaction African American Anticholesteremic Agents Diabetes Mellitus Factor VIIIC factor V Leiden Freezing Genetic Polymorphism Hydroxymethylglutaryl-CoA Reductase Inhibitors Immunoturbidimetric Assay Index, Body Mass Lipids Physicians Plasma Prothrombin Warfarin Woman

Most recents protocols related to «Activated Partial Thromboplastin Time»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Activated Partial Thromboplastin Time Ellagic Acid Factor VIII Plasma Silicon Dioxide
PEA was performed from median sternotomy, the patient was cooled to 18°C to 20°C using cardiopulmonary bypass (CBP), and bilateral PEA was performed under deep hypothermic circulatory arrest. Unfractionated heparin (Leo Pharmaceutical Products, Denmark) was used for intraoperative anticoagulation monitored by activated clotting time (ACT) (target > 480 s Kaolin-ACT, Medtronic.Inc. ACTII, Minneapolis, MN, USA). Before the initiation of CBP, 500 to 1000 ml of blood was harvested, and returned to the patient after weaning off CPB, heparin reversal by protamine sulfate, and decannulation. During CPB to maintain patients’ volume status and to minimize the use of crystalloids (plasmalyte 50 mg/ml, Baxter) and possible volume overload autologous blood transfusion (cell saver), allogenic red blood cell (RBC) transfusions (Hb < 60 g/l), 2 to 6 units of solvent-detergent treated standardized plasma (Octaplas®, Octapharma AG, Lachen, Switzerland) or albumin 20% were used. Tranexamic acid was used 30 mg/kg intravenously before the surgical incision and again 15 mg/kg every 2 h for the duration of CPB. ACT was controlled every 20 min on CPB and 3 min after each heparin bolus. After CPB, administration of protamine and harvested blood infusion, coagulation status was controlled (heparinase-ACT, complete blood count, APTT, PT, fibrinogen, AT and D-dimer). Postoperatively in the operation room allogenic RBC were transfused if Hb < 90 g/l or Hct < 30%. The threshold for platelet transfusion was the platelet count <100 ×109/l and for standardized plasma, Octaplas®, PT < 30%.
Full text: Click here
Publication 2023
Activated Partial Thromboplastin Time Albumins BLOOD Blood Transfusion, Autologous Cardiopulmonary Bypass Cells Circulatory Arrest, Deep Hypothermia Induced Complete Blood Count Detergents Erythrocytes fibrin fragment D Fibrinogen Heparin Heparin Lyase Kaolin Median Sternotomy Patients Pharmaceutical Preparations Plasma Plasmalyte A Platelet Counts, Blood Platelet Transfusion Protamines Red Blood Cell Transfusion Solutions, Crystalloid Solvents Sulfate, Protamine Surgical Wound Tranexamic Acid
The following coagulation assays (reagent and unit in parenthesis) in citrated (3.2%) plasma were analyzed at the local Central Coagulation Laboratory (HUSLAB of Helsinki University Hospital): FVIII (FVIII:C one-stage clotting assay [IU/dl], pathromtin SL and FVIII deficient plasma), fibrinogen (Clauss method [g/l], HemosIL Q.F.A.Thrombin, Werfen, Barcelona, Spain; D-dimer [mg/l] HemosIL D-Dimer HS 500), antithrombin (AT [%], a chromogenic assay Berichrom Antithrombin III), thrombin time ([s], BC Thrombin reagent, Siemens), activated partial thromboplastin time (APTT [s], Actin FSL®, Siemens) and anti-FXa activity (anti-FXa [IU/ml], HemosIL Liquis Anti-Xa, Mediq Suomi Oy). We acquired data of these coagulation markers preoperatively and from the days 1, 2, 3, 7, 14, 30, 90, and 12 months after the operation, if available.
In addition, we measured the dynamics of white blood cell (WBC) count, C-reactive protein (CRP, mg/l), and platelet count (109/l) from the same time points. Preoperative plasma values of prothrombin time (Medirox Owren's PT [%] Medirox, Nyköping, Sweden), FXIII (F-XIII, %), VWF antigen (VWF:Ag, %) and VWF glycoprotein GPIb binding activity (VWF:Act, %), homocysteine (Hcyst, µmol/l), low-density lipoprotein (mmol/l), and triglycerides (Trigly, mmol/l) were collected. Additionally, patients were screened for protein C and S deficiencies, antiphospholipid antibodies as well as Factor V Leiden and FII G20210A mutations.
Full text: Click here
Publication 2023
Actins Activated Partial Thromboplastin Time Antigens Antiphospholipid Antibodies Antithrombin III azo rubin S Biological Assay Coagulation, Blood C Reactive Protein factor V Leiden fibrin fragment D Fibrinogen Glycoproteins Heparin, Low-Molecular-Weight Homocysteine Leukocyte Count Low-Density Lipoproteins Mutation Patients Plasma Platelet Counts, Blood Protein C Tests, Blood Coagulation Thrombin Times, Prothrombin Times, Reptilase Triglycerides

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Activated Partial Thromboplastin Time Antithrombin III Continuous Positive Airway Pressure COVID 19 C Reactive Protein Disseminated Intravascular Coagulation Factor VIII Factor VIII-Related Antigen Fibrinogen Hemoglobin Heparin Heparin, Low-Molecular-Weight Index, Body Mass International Normalized Ratio Protein C Protein S SARS-CoV-2 Times, Prothrombin Veins

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Activated Partial Thromboplastin Time Antithrombin III BLOOD Citrates C Reactive Protein Creatinine Diagnosis Edetic Acid Factor VIII Factor VIII-Related Antigen fibrin fragment D Fibrinogen Heparin Sodium Patient Admission Patients Protein C protein S, human Serum

Top products related to «Activated Partial Thromboplastin Time»

Sourced in Japan, China, United States
The CS-5100 is a fully automated coagulation analyzer designed for high-volume clinical laboratories. It performs a range of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen concentration determination. The system is capable of processing a large number of samples with high efficiency and accuracy.
Sourced in Japan, United Kingdom, France, Germany
The CS2100i is a compact and fully automated coagulation analyzer designed for clinical laboratories. It performs a range of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen. The CS2100i features a user-friendly interface and is capable of handling a variety of sample types, providing reliable and efficient coagulation testing.
Sourced in Japan, Germany, United States
The CA-1500 is an automated coagulation analyzer manufactured by Sysmex. It is designed for the measurement and analysis of coagulation parameters in clinical laboratory settings. The CA-1500 utilizes optical detection methods to perform a variety of coagulation tests, providing reliable and accurate results to support patient care.
Sourced in Japan, Germany, United Kingdom, United States, Brazil
The XE-2100 is a hematology analyzer designed for automated blood cell analysis. It provides comprehensive analysis of various blood cell types, including red blood cells, white blood cells, and platelets. The XE-2100 is capable of performing a wide range of hematological tests and measurements to support clinical decision-making.
Sourced in Germany, Japan
Thromborel S is a laboratory product manufactured by Siemens. It is used to determine prothrombin time (PT) in human plasma samples.
Sourced in Germany, Japan, United States
Pathromtin SL is a laboratory reagent used in the measurement of the activated partial thromboplastin time (aPTT), a test that evaluates the intrinsic and common coagulation pathways. It is a liquid preparation containing phospholipids, activators, and stabilizers.
Sourced in Germany
Actin FS is a high-quality laboratory equipment product designed for use in scientific research and testing. It is a fundamental component in the study of cellular structure and function. The core function of Actin FS is to facilitate the observation and analysis of actin, a key structural protein found in eukaryotic cells.
Sourced in United States, Germany, Italy
SynthASil is a laboratory instrument designed for the synthesis of oligonucleotides. It utilizes a proprietary synthesis platform to efficiently produce synthetic DNA and RNA sequences.
Sourced in Japan, Germany
The CA-7000 is an automated coagulation analyzer developed by Sysmex. It is designed to perform a variety of coagulation tests, including prothrombin time (PT), activated partial thromboplastin time (APTT), and other coagulation-related assays. The CA-7000 features high throughput, precise results, and streamlined workflow to support laboratory testing needs.
Sourced in Japan
Thrombocheck APTT-SLA is a laboratory reagent used to perform activated partial thromboplastin time (APTT) testing. The core function of this product is to measure the clotting time of a patient's blood sample, which is an important indicator of the body's ability to form blood clots.

More about "Activated Partial Thromboplastin Time"

Activated Partial Thromboplastin Time (aPTT) is a crucial laboratory test used to assess the functionality of the intrinsic and common pathways of the blood coagulation cascade.
This test measures the time it takes for a blood sample to clot, and is commonly employed to monitor patients undergoing anticoagulant therapy, such as heparin treatment, as well as to diagnose certain bleeding disorders.
The aPTT test is closely related to other coagulation assays, including the Thromborel S, Pathromtin SL, Actin FS, SynthASil, and CA-7000 tests, which provide similar information about the coagulation system.
These tests may be used in conjunction with the aPTT to provide a more comprehensive understanding of a patient's clotting profile.
To optimize aPTT research, AI-driven comparisons can be utilized to locate the best protocols from literature, pre-prints, and patents, enhancing reproducibilty and accuaracy.
This approach, facilitated by tools like PubCompare.ai, can help take aPTT research to the next level by improving the reliability and accuracy of results.
By leveraging these insights and technologies, researchers can gain a deeper understanding of the aPTT test and its application in various clinical settings, including the monitoring of anticoagulant therapy using devices like the CS-5100, CS2100i, CA-1500, and XE-2100 analyzers.
This knowledge can lead to improved patient outcomes and advancements in the field of coagulation research.